TTR and cardiac amyloidosis: AG10 is a novel, potent,and selective oral transthyretin stabilizer, which was developed totreat transthyretin amyloid cardiomyopathy (ATTR-CM) (currently inPhase III clinical trials)., It was hypothesizedthat the hydrophilic spacers in the transthyretin protein (TTR, atransport protein found in plasma and cerebrospinal fluid) ligandswill maintain the overall hydrophilicity of TFMs, limiting their passivediffusion into PSMA(−) cells.